Organogenesis Holdings ( (ORGO) ) has released its Q3 earnings. Here is a breakdown of the information Organogenesis Holdings presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Organogenesis Holdings Inc. is a prominent player in the regenerative medicine sector, focusing on advanced wound care and surgical and sports medicine markets, offering a diverse range of innovative products.
In its third-quarter 2025 financial report, Organogenesis Holdings Inc. announced record-breaking revenue figures and an upward revision of its 2025 financial guidance, highlighting robust performance and strategic positioning in the market.
The company reported a net product revenue of $150.5 million for the third quarter of 2025, marking a 31% increase from the previous year. This growth was driven by a 31% rise in revenue from Advanced Wound Care products and a 25% increase in Surgical & Sports Medicine products. Net income for the quarter also saw a significant rise to $21.6 million, compared to $12.3 million in the same period last year. Additionally, the company achieved an adjusted EBITDA of $30.1 million, reflecting a substantial increase from the previous year.
Despite a decrease in net product revenue for the first nine months of 2025 compared to 2024, the company remains optimistic, with updated fiscal year guidance projecting net product revenue between $500 million and $525 million. This represents a year-over-year increase of 4% to 9%. The company also anticipates net income between $8.6 million and $25.4 million, with adjusted EBITDA projected to range from $45.5 million to $68.3 million.
Looking ahead, Organogenesis Holdings Inc. is poised to leverage its strong portfolio of regenerative technologies and capitalize on new market opportunities, positioning itself for continued growth and success in 2026 and beyond.